Frost & Sullivan Independent Equity Research
RedHill Biopharma announces positive top-line results from Phase III study of RHB-104 in Crohn’s Disease; remission rates at week-52 are low by market comparison; Redhill plans to raise additional capital to support future clinical development; target price remains at NIS 2.59
![redhill redhill](https://www.frostequityresearch.com/wp-content/uploads/elementor/thumbs/redhill-nx7oeooppwzdf81hcfxh8nobo63au3cco6m1rxg31y.png)
Company: RedHill Biopharma
Sector: Pharmaceuticals
Report type: Immediate Report
Published on: 31 July, 2018